- The disease
- Radiology departments in hospitals and imaging centres generate large volumes of medical images, including X-rays, CT scans, and MRIs, that clinicians need to view, store, and retrieve rapidly. A PACS (picture archiving and communication system) is the software infrastructure that manages this workflow. Delays or inefficiencies in image rendering can affect diagnostic throughput. The market spans health systems of all sizes, with large academic medical centres typically running the most demanding imaging volumes.
- What the asset is trying to do
- Visage 7 is a commercially available PACS and diagnostic imaging viewer developed by Pro Medicus Limited. The platform uses a thin-client streaming architecture, meaning image processing occurs on centralised servers rather than on the radiologist's local workstation, and only the rendered image pixels are transmitted to the end user. This approach differs from traditional PACS products, which typically require large image files to be downloaded to local hardware before viewing. Pro Medicus holds patents related to this streaming technology (per Pro Medicus ASX announcements and company filings).
- What the trial is measuring, and why it matters
- Visage 7 is a regulatory-cleared commercial product, not a clinical-stage investigational asset, so it is not evaluated in a prospective clinical trial with formal endpoints. Customers evaluate the platform on operational metrics such as image load times, system uptime, integration with hospital information systems, and total cost of ownership. Contract renewals and new contract signings, as disclosed via ASX announcements, reflect ongoing commercial adoption.
- Efficacy benchmarks in this setting
- Visage 7 is not an investigational therapy and does not have clinical efficacy endpoints such as response rates or survival figures. No head-to-head randomised trial data comparing PACS platforms on patient outcomes has been identified in the input data provided. As a result, the standard efficacy benchmarking framework used for drug pipeline assets does not apply here.
- Commercial context
- Visage 7 is a commercially deployed product and is Pro Medicus's primary revenue-generating asset (per Pro Medicus company filings). Recent disclosed contract activity includes a 5-year, A$16 million renewal with Ohio State University (OSU) (per ASX announcement, 2026-06-03), a 5-year, A$28 million renewal with Allegheny Health Network (per ASX announcement, 2026-05-31), and a 7-year, A$16 million contract with TidalHealth (per ASX announcement, 2026-05-31). Pro Medicus also signed a Heads of Agreement with Echo IQ covering a finance facility and reseller agreement (per ASX announcement, 2026-06-24). The PACS and diagnostic imaging software market includes established competitors such as Sectra, Philips, and Fujifilm, among others; no curated competitor trial data has been provided for this asset.